CDER’s Office of Compliance Kicks Off Annual Report Season with Rundown of 2023’s Major Public Health Enforcement Initiatives
FDA Law Blog: Biosimilars
JANUARY 22, 2024
Claud — The Office of Compliance (OC) at FDA’s Center for Drug Evaluation and Research (CDER) had a role in many of the major public health enforcement matters you may have read about last year. Clinical Trials. By John W.M. Drug Supply Chain.
59 
Let's personalize your content